

Resource Summary Report

Generated by [RRID](#) on Aug 20, 2026

pBabe-Kras G12C

RRID:Addgene_58901

Type: Plasmid

Proper Citation

RRID:Addgene_58901

Plasmid Information

URL: <http://www.addgene.org/58901>

Proper Citation: RRID:Addgene_58901

Insert Name: KRAS

Organism: Homo sapiens

Bacterial Resistance: Ampicillin

Vector Backbone Description: Backbone Marker:unknown; Backbone Size:5169; Vector Backbone:pBabe-puro; Vector Types:Mammalian Expression, Retroviral; Bacterial Resistance:Ampicillin

Plasmid Name: pBabe-Kras G12C

Relevant Mutation: G12C mutation

Record Creation Time: 20220422T222340+0000

Record Last Update: 20260815T081719+0000

Ratings and Alerts

No rating or validation information has been found for pBabe-Kras G12C.

No alerts have been found for pBabe-Kras G12C.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Shrivastava A, et al. (2026) Mutant KRAS-driven selective mRNA translation reveals mechanisms and therapeutic vulnerabilities in cancer. *Cell reports*, 45(6), 117520.

Shin DH, et al. (2025) Targeting TGF- β -Smad2/3-JNK1-mediated SIRT1 activity overcomes the chemoresistance of KRAS mutation lung cancer. *Experimental & molecular medicine*, 57(9), 2022.

Foote JB, et al. (2025) A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer. *Cancer research*, 85(5), 956.

Mateo-Victoriano B, et al. (2025) Oncogenic KRAS addiction states differentially influence MTH1 expression and 8-oxodGTPase activity in lung adenocarcinoma. *Redox biology*, 82, 103610.

Tripathi BK, et al. (2024) The pro-oncogenic noncanonical activity of a RAS•GTP:RanGAP1 complex facilitates nuclear protein export. *Nature cancer*, 5(12), 1902.

Shin DH, et al. (2023) Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer. *Experimental & molecular medicine*, 55(10), 2220.

Huynh MV, et al. (2022) Oncogenic KRAS G12C: Kinetic and redox characterization of covalent inhibition. *The Journal of biological chemistry*, 298(8), 102186.

Ramakrishnan G, et al. (2022) NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma. *Cell reports*, 41(6), 111623.

Tripathi P, et al. (2022) Pixantrone confers radiosensitization in KRAS mutated cancer cells by suppression of radiation-induced prosurvival pathways. *Free radical biology & medicine*, 190, 351.

Liu J, et al. (2021) A CRISPR-Cas9 repressor for epigenetic silencing of KRAS. *Pharmacological research*, 164, 105304.

Sad K, et al. (2021) Prochlorperazine enhances radiosensitivity of non-small cell lung carcinoma by stabilizing GDP-bound mutant KRAS conformation. *Free radical biology & medicine*, 177, 299.

Inoue S, et al. (2019) Uterine adenomyosis is an oligoclonal disorder associated with KRAS mutations. *Nature communications*, 10(1), 5785.

Hrustanovic G, et al. (2015) RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. *Nature medicine*, 21(9), 1038.

Wang ZD, et al. (2015) Targeting oncogenic KRAS in non-small cell lung cancer cells by phenformin inhibits growth and angiogenesis. *American journal of cancer research*, 5(11), 3339.